Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Medea Gegia

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Clinical Chemistry|July 4, 2009
Monitoring therapeutic efficacy by real-time detection of Mycobacterium tuberculosis mRNA in sputumNino Mdivani, Haijing Li, Maka Akhalaia, et al.
Antimicrobial Agents and Chemotherapy|December 12, 2007
Prevalence of and molecular basis for tuberculosis drug resistance in the Republic of Georgia: validation of a QIAplex system for detection of drug resistance-related mutationsMedea Gegia, Nino Mdivani, Rodrigo E Mendes, et al.
The European Respiratory Journal|August 20, 2021
World Health Organization treatment outcome definitions for tuberculosis: 2021 updateNguyen Nhat Linh, Kerri Viney, Medea Gegia, et al.
The European Respiratory Journal|June 27, 2020
Changes in treatment for multidrug-resistant tuberculosis according to national incomeNakwon Kwak, Nicholas Winters, Jonathon R Campbell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2023
Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-AnalysisBelén P Solans, Agathe Béranger, Kendra Radtke, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 25, 2024
Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort StudyHannah Morgan, Norbert Ndjeka, Tasnim Hasan, et al.
Bulletin of the World Health Organization|January 25, 2012
Eliminating the category II retreatment regimen from national tuberculosis programme guidelines: the Georgian experienceJennifer Furin, Medea Gegia, Carole Mitnick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 24, 2023
The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysisTasnim Hasan, Ellie Medcalf, Bern-Thomas Nyang'wa, et al.
Plos One|October 5, 2023
Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatmentNicholas Winters, Mireille E Schnitzer, Jonathon R Campbell, et al.
Emerging Infectious Diseases|February 22, 2019
Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant TuberculosisMuhammad Osman, Elizabeth P Harausz, Anthony J Garcia-Prats, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Clinical Chemistry|July 4, 2009
Monitoring therapeutic efficacy by real-time detection of Mycobacterium tuberculosis mRNA in sputumNino Mdivani, Haijing Li, Maka Akhalaia, et al.
Antimicrobial Agents and Chemotherapy|December 12, 2007
Prevalence of and molecular basis for tuberculosis drug resistance in the Republic of Georgia: validation of a QIAplex system for detection of drug resistance-related mutationsMedea Gegia, Nino Mdivani, Rodrigo E Mendes, et al.
The European Respiratory Journal|August 20, 2021
World Health Organization treatment outcome definitions for tuberculosis: 2021 updateNguyen Nhat Linh, Kerri Viney, Medea Gegia, et al.
The European Respiratory Journal|June 27, 2020
Changes in treatment for multidrug-resistant tuberculosis according to national incomeNakwon Kwak, Nicholas Winters, Jonathon R Campbell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2023
Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-AnalysisBelén P Solans, Agathe Béranger, Kendra Radtke, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 25, 2024
Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort StudyHannah Morgan, Norbert Ndjeka, Tasnim Hasan, et al.
Bulletin of the World Health Organization|January 25, 2012
Eliminating the category II retreatment regimen from national tuberculosis programme guidelines: the Georgian experienceJennifer Furin, Medea Gegia, Carole Mitnick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 24, 2023
The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysisTasnim Hasan, Ellie Medcalf, Bern-Thomas Nyang'wa, et al.
Plos One|October 5, 2023
Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatmentNicholas Winters, Mireille E Schnitzer, Jonathon R Campbell, et al.
Emerging Infectious Diseases|February 22, 2019
Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant TuberculosisMuhammad Osman, Elizabeth P Harausz, Anthony J Garcia-Prats, et al.
Pageof 3